Before you prescribed AUSTEDO for his tardive dyskinesia (TD), he was concerned about people noticing his movements.1

Now expressing
himself is
what moves him

Man and son enjoying ice cream cones on park bench. “Now expressing himself is what moves him” written next to them.
 Man and son enjoying ice cream cones on park bench. “Now expressing himself is what moves him” written next to them.

Models are not actual patients.

Models are not actual patients.

*Overall compliance based on pill counts.

Purple video icon.

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.6

VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Data on file. North Wales, PA: Teva Neuroscience, Inc. 4. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317-1323. doi:10.1136/jnnp-2018-319918 5. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 6. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238. doi:10.2147/DDDT.S133205